HELSINKI: Nanoform Finland Plc (Nanoform), an innovative nanoparticle medicine enabling company, announced a new near-term business target.

In 2021 Nanoform targets at least 12 new non-GMP1 (pre-clinical) customer projects and at least one new GMP (clinical) customer project. The company reported 2 non-GMP customer projects in 2019 and 7 non-GMP customer projects in Q1-Q3/2020. Nanoform's Q4/2020 report is due February 26th, 2021.

Nanoform also reiterated its previously announced First Biologics PoC2 project in 2021, as well as its 2025 mid-term business targets of

to nanoform at least 50 new APIs3 annually
to have in place 25 operating production lines of which 5 to 10 are expected to be GMP production lines
over 90 percent gross margin
approximately 200 employees
to be cash flow positive

In December 2020 Nanoform achieved all its near-term business targets for 2020 and 2021 announced in relation to the IPO (June 4th, 2020).

Nanoform sets a new near-term business target for 2021

Liked This Article? Be The First To Share it!

Class

Send